Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.
Zuccari G, et al. Among authors: pistoia v.
J Control Release. 2015 Aug 10;211:44-52. doi: 10.1016/j.jconrel.2015.05.286. Epub 2015 May 29.
J Control Release. 2015.
PMID: 26031842